Literature DB >> 22842875

Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.

Manuela Neumann1, Chiara F Valori, Olaf Ansorge, Hans A Kretzschmar, David G Munoz, Hirofumi Kusaka, Osamu Yokota, Kenji Ishihara, Lee-Cyn Ang, Juan M Bilbao, Ian R A Mackenzie.   

Abstract

Accumulation of the DNA/RNA binding protein fused in sarcoma (FUS) as inclusions in neurons and glia is the pathological hallmark of amyotrophic lateral sclerosis patients with mutations in FUS (ALS-FUS) as well as in several subtypes of frontotemporal lobar degeneration (FTLD-FUS), which are not associated with FUS mutations. Despite some overlap in the phenotype and neuropathology of FTLD-FUS and ALS-FUS, significant differences of potential pathomechanistic relevance were recently identified in the protein composition of inclusions in these conditions. While ALS-FUS showed only accumulation of FUS, inclusions in FTLD-FUS revealed co-accumulation of all members of the FET protein family, that include FUS, Ewing's sarcoma (EWS) and TATA-binding protein-associated factor 15 (TAF15) suggesting a more complex disturbance of transportin-mediated nuclear import of proteins in FTLD-FUS compared to ALS-FUS. To gain more insight into the mechanisms of inclusion body formation, we investigated the role of Transportin 1 (Trn1) as well as 13 additional cargo proteins of Transportin in the spectrum of FUS-opathies by immunohistochemistry and biochemically. FUS-positive inclusions in six ALS-FUS cases including four different mutations did not label for Trn1. In sharp contrast, the FET-positive pathology in all FTLD-FUS subtypes was also strongly labeled for Trn1 and often associated with a reduction in the normal nuclear staining of Trn1 in inclusion bearing cells, while no biochemical changes of Trn1 were detectable in FTLD-FUS. Notably, despite the dramatic changes in the subcellular distribution of Trn1 in FTLD-FUS, alterations of its cargo proteins were restricted to FET proteins and no changes in the normal physiological staining of 13 additional Trn1 targets, such as hnRNPA1, PAPBN1 and Sam68, were observed in FTLD-FUS. These data imply a specific dysfunction in the interaction between Trn1 and FET proteins in the inclusion body formation in FTLD-FUS. Moreover, the absence of Trn1 in ALS-FUS provides further evidence that ALS-FUS and FTLD-FUS have different underlying pathomechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842875     DOI: 10.1007/s00401-012-1020-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  32 in total

1.  Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma.

Authors:  Jeremy J Ryan; Macy L Sprunger; Kayla Holthaus; James Shorter; Meredith E Jackrel
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

2.  The FUS about arginine methylation in ALS and FTLD.

Authors:  Hannah M Kaneb; Patrick A Dion; Guy A Rouleau
Journal:  EMBO J       Date:  2012-10-19       Impact factor: 11.598

Review 3.  Fused in Sarcoma Neuropathology in Neurodegenerative Disease.

Authors:  Ian R A Mackenzie; Manuela Neumann
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

Review 4.  Inherited and Sporadic Amyotrophic Lateral Sclerosis and Fronto-Temporal Lobar Degenerations arising from Pathological Condensates of Phase Separating Proteins.

Authors:  Michael Fernandopulle; GuoZhen Wang; Jonathon Nixon-Abell; Seema Qamar; Varun Balaji; Ryuta Morihara; Peter H St George-Hyslop
Journal:  Hum Mol Genet       Date:  2019-11-21       Impact factor: 6.150

Review 5.  Traffic jam at the nuclear pore: All roads lead to nucleocytoplasmic transport defects in ALS/FTD.

Authors:  Claudia Fallini; Bilal Khalil; Courtney L Smith; Wilfried Rossoll
Journal:  Neurobiol Dis       Date:  2020-03-14       Impact factor: 5.996

6.  FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.

Authors:  Qiudong Deng; Christopher J Holler; Georgia Taylor; Kathryn F Hudson; William Watkins; Marla Gearing; Daisuke Ito; Melissa E Murray; Dennis W Dickson; Nicholas T Seyfried; Thomas Kukar
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

Review 7.  Development of disease-modifying drugs for frontotemporal dementia spectrum disorders.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Davide Seripa; Antonio Daniele; Mark Watling; Gianluigi Giannelli
Journal:  Nat Rev Neurol       Date:  2020-03-23       Impact factor: 42.937

8.  Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS.

Authors:  Thomas A Ravenscroft; Matt C Baker; Nicola J Rutherford; Manuela Neumann; Ian R Mackenzie; Keith A Josephs; Bradley F Boeve; Ronald Petersen; Glenda M Halliday; Jillian Kril; John C van Swieten; William W Seeley; Dennis W Dickson; Rosa Rademakers
Journal:  Neurobiol Aging       Date:  2013-04-28       Impact factor: 4.673

Review 9.  Nuclear pore complexes in development and tissue homeostasis.

Authors:  Valeria Guglielmi; Stephen Sakuma; Maximiliano A D'Angelo
Journal:  Development       Date:  2020-12-15       Impact factor: 6.868

Review 10.  Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases.

Authors:  Hong Joo Kim; J Paul Taylor
Journal:  Neuron       Date:  2017-10-11       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.